بدائل البحث:
significantly increased » significant increase (توسيع البحث)
increased decrease » increased release (توسيع البحث), increased crash (توسيع البحث)
largest decrease » marked decrease (توسيع البحث)
larger decrease » marked decrease (توسيع البحث)
significantly increased » significant increase (توسيع البحث)
increased decrease » increased release (توسيع البحث), increased crash (توسيع البحث)
largest decrease » marked decrease (توسيع البحث)
larger decrease » marked decrease (توسيع البحث)
-
1841
-
1842
-
1843
Results of adhesive filling rate (AFR) at abutment shoulder filling rate in each group.
منشور في 2025الموضوعات: -
1844
-
1845
Cement retention force values(N) for each group in the cement retention strength test.
منشور في 2025الموضوعات: -
1846
-
1847
-
1848
-
1849
-
1850
-
1851
-
1852
-
1853
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
1854
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
1855
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
منشور في 2025"…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
-
1856
-
1857
-
1858
-
1859
-
1860